Table 3.
Baseline characteristics of randomly assigned patients with CKDa
| Characteristic Invasive/Conservative Strategies | TIMI IIIB
|
FRISC II
|
TACTICS-TIMI 18
|
VINO
|
ICTUS
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| GFR <30 | GFR 30 to 60 | GFR <30 | GFR 30 to 60 | GFR <30 | GFR 30 to 60 | GFR <30 | GFR 30 to 60 | GFR <30 | GFR 30 to 60 | |
| No. randomly assigned | 102/114 | 119/114 | 2/2 | 209/216 | 17/12 | 199/201 | 4/6 | 8/11 | 5/3 | 53/56 |
| Age (yr; mean) | 60/61 | 65/65 | 74/71 | 70/69 | 69/67 | 68/68 | 68/65 | 65/65 | 73/78 | 72/72 |
| Men (n [%]) | 72/81 (71/71) | 61/49 (51/43) | 0/1 (0/50) | 115/104 (55/48) | 6/6 (35/50) | 106/101 (53/50) | 2/2 (50/33) | 4/6 (50/55) | 3/3 (60/100) | 31/29 (58/52) |
| White race (n [%]) | 102/112 (100/98) | 100/89 (84/78) | 2/2 (100/100) | 208/216 (100/100) | 12/12 (71/100) | 159/157 (80/78) | 4/6 (100/100) | 8/11 (100/100) | NA | NA |
| Diabetes (n [%]) | 8/10 (8/9) | 9/12 (8/11) | 0/0 (0/0) | 39/36 (19/17) | 12/4 (71/33) | 67/63 (34/31) | 3/4 (75/67) | 5/6 (63/55) | 2/1 (40/33) | 13/13 (25/23) |
| Previous MI (n [%]) | 47/52 (46/46) | 52/37 (44/32) | 1/1 (50/50) | 79/65 (38/30) | 7/6 (41/50) | 86/89 (43/44) | 1/3 (25/50) | 5/6 (63/55) | 2/1 (40/33) | 24/16 (45/29) |
| ST deviations (n [%]) | 48/40 (47/35) | 41/47 (34/41) | 1/1 (50/50) | 111/124 (53/57) | 7/5 (41/42) | 82/76 (41/38) | 3/5 (75/83) | 5/7 (63/64) | 5/1 (100/33) | 27/19 (51/34) |
| T-wave inversion (n [%]) | 36/43 (35/38) | 51/64 (43/56) | 2/2 (100/100) | 144/162 (69/75) | 6/7 (35/58) | 74/78 (37/39) | 1/1 (25/17) | 3/4 (38/36) | 1/0 (20/0) | 9/8 (17/14) |
| Thrombolytic therapy (n [%]) | 51/58 (50/51) | 58/52 (49/46) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) | 0/0 (0/0) |
| Coronary revascularization during follow-up (n [%]) | 68/73 (67/64) | 79/71 (66/62) | 1/1 (50/50) | 157/100 (75/46) | 10/7 (59/58) | 113/83 (57/41) | 1/2 (25/33) | 5/5 (63/45) | 1/0 (20/0) | 37/27 (70/48) |
| PCI during initial hospitalization (n [%]) | 63/52 (62/46) | 75/49 (63/43) | 1/1 (50/50) | 154/38 (74/18) | 8/2 (47/17) | 72/36 (36/18) | 1/2 (25/33) | 5/5 (63/45) | 1/0 (20/0) | 35/17 (66/30) |
| CABG at initial hospitalization (n [%]) | 26/22 (25/19) | 33/25 (28/22) | 1/1 (50/50) | 89/23 (43/11) | 2/2 (12/17) | 35/26 (18/13) | 1/1 (25/17) | 4/4 (50/36) | 0/0 (0/0) | 11/7 (21/13) |
| 1-yr mortality (n [%]) | 5/6 (5/5) | 6/11 (5/10) | 0/0 (0/0) | 10/19 (5/9) | 3/1 (18/8) | 9/11 (5/5) | 1/3 (25/50) | 0/3 (0/27) | 0/2 (0/67) | 8/3 (15/5) |
a
Patients with stages 4 to 5 chronic kidney disease (CKD) were primarily enrolled in the TIMI IIIB trial. Approximately half of the patients with CKD in the TIMI IIIB trial underwent thrombolysis. Thrombolysis was not performed in the other trials. PCI, percutaneous revascularization.